These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 8857557)

  • 1. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry.
    Brøsen K
    Ther Drug Monit; 1996 Aug; 18(4):393-6. PubMed ID: 8857557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
    Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
    Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of CYP3A4 in the metabolism of bromperidol in vitro.
    Sato S; Someya T; Shioiri O; Koitabashi T; Inoue Y
    Pharmacol Toxicol; 2000 Mar; 86(3):145-8. PubMed ID: 10752674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
    Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
    Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
    Uttamsingh V; Lu C; Miwa G; Gan LS
    Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
    Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
    Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
    Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
    Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
    J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes.
    Emoto C; Iwasaki K
    Xenobiotica; 2007 Sep; 37(9):986-99. PubMed ID: 17896325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
    Frye RF; Branch RA
    Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.
    Minoletti C; Dijols S; Dansette PM; Mansuy D
    Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?
    Tanaka E; Kurata N; Yasuhara H
    J Clin Pharm Ther; 2003 Jun; 28(3):157-65. PubMed ID: 12795773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
    Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
    Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of cytochrome P450 activity by a five-drug cocktail approach.
    Zhu B; Ou-Yang DS; Chen XP; Huang SL; Tan ZR; He N; Zhou HH
    Clin Pharmacol Ther; 2001 Nov; 70(5):455-61. PubMed ID: 11719732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6.
    Damkier P; Brøsen K
    Clin Pharmacol Ther; 2000 Aug; 68(2):199-209. PubMed ID: 10976551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects.
    Chen XP; Tan ZR; Huang SL; Huang Z; Ou-Yang DS; Zhou HH
    Clin Pharmacol Ther; 2003 Mar; 73(3):264-71. PubMed ID: 12621391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
    He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
    Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dehydrogenation of indoline by cytochrome P450 enzymes: a novel "aromatase" process.
    Sun H; Ehlhardt WJ; Kulanthaivel P; Lanza DL; Reilly CA; Yost GS
    J Pharmacol Exp Ther; 2007 Aug; 322(2):843-51. PubMed ID: 17502430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
    Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
    J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.